Acquisitions of laboratories, imaging and dialysis centers declined in 2016, as each of the sectors faced headwinds.
Mallinckrodt is just one of many big-name pharma companies that are divesting non-core businesses in order to target specific therapeutics and disease areas.
You can’t get much more “specialty” in the specialty pharmacy business than to deal in radiopharmaceuticals. Two recent deals, announced in August, show this area is heating up. IBA Molecular, a global maker and distributor of radiopharmaceutical products, agreed to pay approximately $613 million for Mallinckrodt‘s (NYSE: MNK) nuclear imaging business, including a portfolio of […]